Glooko Acquires Germany-Based xbird, a Medical AI Company

Using the latest AI and machine learning, xbird's technology has the capability to identify health risks for people with diabetes by interpreting medical and behavioral data in a targeted manner and provide customized recommendations and behavioral nudges. Sensors via smartphones and wearables record a user's movements and analyze the data to create individualized behavioral profiles and personalized nudges to change patient behavior and lifestyle decisions. The addition of xbird expands Glooko's advanced analytics capabilities and tools, further broadening Glooko's platform offerings.

"We are thrilled to welcome the xbird team to the Glooko family. Our investment in xbird represents Glooko's strategic commitment to machine learning and customized digital coaching for patients with chronic conditions," said Russ Johannesson, Glooko's Chief Executive Officer. "Among the many JITAI companies in the digital health landscape, xbird clearly has a superior solution, and has built successful partnerships throughout diabetes device manufacturers and clinical institutions. The combination of Glooko's established global footprint and xbird's exciting JITAI capabilities will allow us to improve patient outcomes."

Sebastian Sujka, Chief Executive Officer and co-founder of xbird stated, "xbird and Glooko are a great fit. We share a commitment to providing solutions that address multiple chronic conditions, delivering measurable outcomes, and we have a common mission to broadly serve all patients in need. Our goal is to continue the design of digital health solutions for those living with these conditions and to make our capabilities accessible to as many patients as possible." Mr. Sujka will join Glooko as the Managing Director of Glooko GmbH, along with all of the xbird staff.

Glooko will integrate the xbird JITAI digital coaching software with its established platform, which is used daily by more than 7500 clinics globally and over 1M users. Glooko plans to enable users of their platform globally to utilize these solutions to better manage their diabetes and related chronic conditions.